Immunitybio Inc Cash Flow Conversion Efficiency
Immunitybio Inc cash flow conversion efficiency. Based on the latest financial reports, Immunitybio Inc (IBRX) has a cash flow conversion efficiency ratio of 1.356x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-68.91 Million) by net assets ($-50.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Immunitybio Inc (2013–2024)
Cash flow conversion efficiency of Immunitybio Inc from 2013 to 2024. This chart illustrates how Immunitybio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Immunitybio Inc (IBRX) share price today for real-time trading data and today's change.
Immunitybio Inc Cash Flow Conversion Ratio Explained
Immunitybio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Immunitybio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunitybio Inc ranked by their cash flow conversion efficiency. Also see Immunitybio Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Home BancShares Inc
NYSE:HOMB
|
0.021x |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
0.022x |
|
Zhongtai Securities Co Ltd
SHG:600918
|
-0.252x |
|
Gates Industrial Corporation plc
NYSE:GTES
|
0.073x |
|
Powertech Technology Inc
TW:6239
|
0.073x |
|
Australian Foundation Investment Company Ltd
AU:AFI
|
0.012x |
|
Tencent Music Entertainment Group
NYSE:TME
|
0.043x |
|
Macronix International Co Ltd
TW:2337
|
0.126x |
Annual Cash Flow Conversion Efficiency for Immunitybio Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Immunitybio Inc from 2013 to 2024. Review IBRX financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-488.13 Million | $-391.24 Million | 0.802x | +28.05% |
| 2023-12-31 | $-585.94 Million | $-366.76 Million | 0.626x | -16.58% |
| 2022-12-31 | $-449.82 Million | $-337.51 Million | 0.750x | -33.31% |
| 2021-12-31 | $-243.91 Million | $-274.42 Million | 1.125x | -22.37% |
| 2020-12-31 | $-118.49 Million | $-171.72 Million | 1.449x | +214.98% |
| 2019-12-31 | $120.68 Million | $-152.11 Million | -1.260x | -190.36% |
| 2018-12-31 | $146.01 Million | $-63.38 Million | -0.434x | -94.75% |
| 2017-12-31 | $218.84 Million | $-48.78 Million | -0.223x | -69.47% |
| 2016-12-31 | $293.42 Million | $-38.59 Million | -0.132x | -85.04% |
| 2015-12-31 | $356.00 Million | $-25.30 Million | -0.071x | +22.43% |
| 2014-12-31 | $58.42 Million | $-5.35 Million | -0.092x | -139.72% |
| 2013-12-31 | $-2.90 Million | $-668.00K | 0.231x | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more